PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
From:
Support Care Cancer. Author manuscript; available in PMC 2013 November 22.
Published in final edited form as:
Support Care Cancer. 2013 September; 21(9): 10.1007/s00520-013-1808-5.
Published online 2013 April 17. doi: 10.1007/s00520-013-1808-5

Table 1

Demographic and clinical characteristics by induction therapy

LEN (−)
N=133
LEN (+)
N=186
Age at BMT [Median (IQR)]59 (52, 65)58 (52, 63)
Sex
 Male69 (52 %)107 (58 %)
 Female64 (48 %)79 (42 %)
Race
 White99 (74 %)142 (76 %)
 Black32 (24 %)39 (21 %)
 Other2 (2 %)5 (3 %)
Durie–Salmon Stage at Diagnosis
 I14/77 (18 %)16/104 (15.3 %)
 II13/77 (17 %)15/104 (14.4 %)
 III50/77 (65 %)73/104 (70.1 %)
Initial Priming Agent
 G-CSF104 (78 %)139 (75 %)
 G-CSF + GMCSF0 (0 %)4 (2 %)
 Cyclophosphamide + G-CSF14 (11 %)14 (8 %)
 Plerixafor + G-CSF15 (11 %)29 (16 %)
Induction cycles [median (IQR)]5 (4, 7)4 (4, 6)

G-CSF granulocyte-colony stimulating factor (filgrastim); GMCSF granulocyte-macrophage colony-stimulating factor (sargramostim); Median IQR median interquartile range represents the middle value between 25th and 75th percentile values